Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00258141|
Recruitment Status : Unknown
Verified November 2005 by J. Uriach and Company.
Recruitment status was: Not yet recruiting
First Posted : November 24, 2005
Last Update Posted : November 24, 2005
|Condition or disease||Intervention/treatment||Phase|
|Allergy||Drug: Rupatadine Drug: Placebo||Phase 4|
Mosquito-bite symptoms include wheals and pruritic bite papules. Oral antihistamines have shown to decrease whealing ang accompanying pruritus in placebo-controlled trials.
Subjects will be treated for 4 days, and exposed to experimental mosquito bite at day 3.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||A Placebo-Controlled, Double-Blind, Cross-Over Study With Rupatadine 10 Mg in 30 Mosquito-Bite Allergic Adult Subjects|
- Bite lesion size (squared mm)
- Pruritus on a Visual Analog Scale
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00258141
|Contact: Timo Reunala, Prof.||(+358) firstname.lastname@example.org|
|Ulappatorin Lääkäriasema||Not yet recruiting|
|Principal Investigator: Leena Ackermann, MD|
|Koskiklinikka, Tampere Lääkärikeskus||Not yet recruiting|
|Tampere, Finland, 33101|
|Principal Investigator: Ari Karppinen, MD|
|Principal Investigator:||Timo Reunala, Prof.||Medical School, University of Tampere and Tampere University Hospital|